Թարգեթ Թերապիայի Արդյունավետությունը Արգանդի Պարանոցի Քաղցկեղի 3-Րդ, 4-Րդ Փուլերի Բուժման Ընթացքում

Cervical cancer remains one of the most common malignant tumors in women, with high mortality rates due to challenges in early diagnosis and detection at initial stages. Despite advances in screening programs, including Pap tests and HPV vaccines, the disease continues to be a significant public health concern. Standard treatment methods include surgery, radiation therapy, and chemotherapy. The evaluation of chemotherapy efficacy, particularly in the use of carboplatin and paclitaxel, is crucial for developing optimal treatment strategies. This study aims to analyze the outcomes of chemotherapy and targeted therapy in patients with locally advanced and metastatic cervical cancer by comparing overall survival (OS) and progression-free survival (PFS) rates. The study includes data from 50 patients treated at the National Oncology Center of Armenia between 2016 and 2023. Patients were classified according to FIGO staging, and their treatment responses were evaluated. The chemotherapy regimens analyzed include paclitaxel + topotecan + bevacizumab, paclitaxel + carboplatin + bevacizumab, and paclitaxel + cisplatin + bevacizumab. The analysis revealed that adding bevacizumab to chemotherapy significantly improved overall survival and progression-free survival. The highest complete response rate (27,5%) was observed in patients receiving the paclitaxel + topotecan + bevacizumab regimen. Partial tumor regression was seen in 47,1% of cases, while disease stabilization was recorded in 21,6%. Only 3,9% of patients experienced disease progression. The results align with international studies (e.g., GOG 240 and KEYNOTE-826), confirming the benefit of targeted therapy. Despite the improved survival rates, the study highlights the need to manage treatment-related toxicities effectively. The findings suggest that incorporating targeted therapy into standard chemotherapy regimens enhances survival outcomes for patients with advanced-stage cervical cancer, offering a promising direction for future treatment protocols.